Market Definition
Ovarian Cancer is one of the most common gynecologic cancers and the fifth leading cause of cancer-related death among women. The principal reason behind a rise in these deaths is the late diagnosis. Hence, with growing awareness among people, governments of numerous countries are bridging the gap between science & life and actively working on building robust healthcare infrastructure. It, in turn, would enable the patients to have better chances of curing ovarian cancer & avoiding the high rates of morbidity & mortality.
Market Insights
The Global Ovarian Cancer Market is projected to grow at a double-digit CAGR during the forecast period, i.e., 2022-27. The market would be driven primarily by the rapidly increasing cases of ovarian cancer, especially in the aging female population, i.e., surging the demand for accurate, reliable, & timely diagnoses of patients to provide them with adequate treatments. It, in turn, is instigating the leading players in the global market to expand their research & development capacities and introduce new equipment & drugs.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| Regions Covered | North America: The US, Canada, Mexico |
| Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe | |
| Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific | |
| South America: Brazil, Rest of Latin America | |
| Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa | |
| Key Companies Profiled |
AstraZeneca PLC, AbbVie Inc., Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Others |
| Unit Denominations | USD Million/Billion |
In addition, the immense support from governments of different countries worldwide through massive investments in R&D activities associated with oncology and favorable policies for practicing medications on patients are also contributing to the growth of the global market.
Many private sector companies & governments are also working on developing robust healthcare facilities to ensure the availability of equipment, drugs, & skilled medical professionals to cater to the varied needs of patients and attract medical tourists.
Moreover, growing awareness among people about such illnesses through different campaigns, healthcare advertisements, and government associations are also propelling the demand for advanced diagnosis & treatment of ovarian cancer patients across several countries worldwide. Furthermore, several research companies are developing medications & therapies that are still undergoing clinical trials, which shall hit the global market in the nearer future.
Nonetheless, the swiftly escalating adoption of combination therapies, owing to their greater OS (overall success) rates & effectiveness than single therapies, further projects lucrative growth prospects for the Global Ovarian Cancer Market through 2027.
